

Research and progress on CIC-2 (Review)

HONGWEI WANG¹, MINGHUI XU², QINGJIE KONG³, PENG SUN⁴,
FENGYUN YAN⁵, WENYING TIAN² and XIN WANG²

¹Department of Ophthalmology, People's Hospital of Jingjiang, Jingjiang, Jiangsu 214500;

²Library, Qiqihar Medical University, Qiqihar, Heilongjiang 161006; ³School of Computer Science and Information Technology, Northeast Normal University, Changchun, Jilin 130024;

⁴Department of Ophthalmology, The First Affiliated Hospital of Jiamusi University, Jiamusi, Heilongjiang 154000;

⁵Assets Division, Harbin University of Science and Technology, Harbin, Heilongjiang 150080, P.R. China

Received March 11, 2016; Accepted February 13, 2017

DOI: 10.3892/mmr.2017.6600

Abstract. Chloride channel 2 (CIC-2) is one of the nine mammalian members of the CIC family. The present review discusses the molecular properties of CIC-2, including CLCN2, CIC-2 promoter and the structural properties of CIC-2 protein; physiological properties; functional properties, including the regulation of cell volume. The effects of CIC-2 on the digestive, respiratory, circulatory, nervous and optical systems are also discussed, in addition to the mechanisms involved in the regulation of CIC-2. The review then discusses the diseases associated with CIC-2, including degeneration of the retina, Sjögren's syndrome, age-related cataracts, degeneration of the testes, azoospermia, lung cancer, constipation, repair of impaired intestinal mucosa barrier, leukemia, cystic fibrosis, leukoencephalopathy, epilepsy and diabetes mellitus. It was concluded that future investigations of CIC-2 are likely to be focused on developing specific drugs, activators and inhibitors regulating the expression of CIC-2 to treat diseases associated

with CIC-2. The determination of CLCN2 is required to prevent and treat several diseases associated with CIC-2.

Contents

1. Introduction
2. Molecular properties of CIC-2
3. Biophysical properties of CIC-2
4. Functional properties of CIC-2
5. Mechanism of CIC-2 regulation by regulators
6. Diseases associated with CIC-2
7. Conclusion

1. Introduction

Chloride channels (CICs) are a type of permeable channel protein for chloride ions or other anions on the cell membrane, and CIC proteins are encoded by genes of the CIC family. CICs have nine family members, which are classified into three distinct subfamilies: CIC-1, CIC-2, CIC-Ka/K1 and CIC-Kb/K2; CIC-3, CIC-4 and CIC-5; and CIC-6 and CIC-7 (1). CIC-2 is one of the nine mammalian members of the CIC family, and was initially isolated from the rat heart and brain (2,3) and then from the rabbit heart (4,5). CIC-2 is a two-pore homodimeric, voltage-gated Cl⁻ channel (5-8). CIC-2 can be activated by hyperpolarization (3,9), cell swelling (2,9), extracellular hypotonicity (2) and extracellular acidification (9,10). CIC-2 is almost ubiquitously expressed (3,11), including in ureteric bud cells (12), intestine (13-17), gastric parietal cells (18,19), the liver (20), lung (11,21-26), rat retina (27), parotid acinar cells (28), guinea pig cardiac muscle (29), neuronal cells (30), rat and human airways (17), bovine trabecular meshwork (31), human trabecular meshwork (32,33) and rat trabecular meshwork (34). In addition, CIC-2 can regulate cell volume (2,4,35), control response to swelling (11,36-39), and regulates post-synaptic responses to GABA and glycine (11,40,41).

Although CIC-2 has a wide variety of properties and functions, reports of CLC-3 prior to 1994 are limited, with only six published between 1953 and 1994. Between 1994 and 2015,

Correspondence to: Professor Xin Wang, Library, Qiqihar Medical University, 333 Bukuibeida Street, Qiqihar, Heilongjiang 161006, P.R. China

E-mail: wangxin5907739@163.com

Abbreviations: CICs, chloride channels; IGE, idiopathic generalized epilepsy; MLC, megalencephalic leukoencephalopathy with subcortical cysts; TLE, temporal lobe epilepsy; IBS, irritable bowel syndrome; CF, cystic fibrosis; LG, lacrimal glands; DIDS, 4,4'-diisothiocyano-2,2'-stilbenedisulfonic acid; CFTR, cystic fibrosis transmembrane conductance regulator; HSN, hereditary sensory neuropathy; JAK2, janus kinase 2; JAK3, janus kinase 3; NEDD4-2, neural precursor cell expressed developmentally downregulated gene 4-like; SGKs, serine/threonine protein kinases; PIKfyve, FYVE finger-containing phosphoinositide kinase; GABA_AR, GABA_A receptor; EP (4), prostaglandin E2 receptor 4

Key words: chloride channel 2, molecular properties, biophysical properties, functional properties, regulation mechanism, chloride channel 2 diseases

CIC-2 attracted increasing attention as CIC-2 was understood to possess several molecular, functional and physiological properties, and be associated with several diseases, including degeneration of the retina, Sjögren's syndrome, age-related cataracts, degeneration of the testes, azoospermia, lung cancer, constipation, repair of impaired intestinal mucosa barrier, leukemia, cystic fibrosis, leukoencephalopathy, epilepsy and diabetes mellitus. However, reviews on CIC-2 are limited. The present review aimed to discuss the molecular, functional and physiological properties of CIC-2, in addition to mechanisms involved in the regulation of CIC-2 and diseases associated with CIC-2.

2. Molecular properties of CIC-2

CLCN2 and CIC-2 promoter. The CIC-2 protein is encoded by the CLCN2 gene, which is composed of 898 amino acids and is located in chromosome 3q27.1. The major transcription start site of the CIC-2 gene has been identified, and is localized 100 bp upstream of the putative translation initiation codon (21). A previous study (42) on the possible evolution of CIC-2 gene suggested that CIC-2 may have evolved by gene duplication, mutation and DNA rearrangement (27,43).

The CIC-2 promoter belongs to a GC-rich and TATA-less class (44). Within the 1,930-bp region, one of three CAAT boxes is close to the CIC-2 coding sequence, and the other two are at the middle (44). Within a 391-bp region upstream, the first three of four GC boxes are conserved in human CIC-2, as reported by Cid *et al.* (21,44).

Structural properties of CIC-2 protein. Despite wide functional diversity, CIC family members share a conserved protein structure, including a transmembrane region, which is involved in chloride anion transport, and two intracellular copies of the cystathionine- β -synthase (CBS) domain (CBS1 and CBS2) (5-8,45,46) and an N-terminus. Therefore, the protein structure of CIC-2 is the same in the other CIC family members (45,46), as shown in Fig. 1.

Several other studies on the structural properties of CIC-2 have reported that the CIC-2 dimer is the minimum functional structure (47), protons act independently from the possible effects of the N-terminus on gating (48) and the hetero-dimerization of CIC-2 can modify the unitary conductance of protopores (49).

3. Biophysical properties of CIC-2

In 1992, it was reported that CIC-2 expressed in *Xenopus* oocytes generates Cl⁻ currents, which activate slowly upon hyperpolarization and show a linear instantaneous current-voltage association (3). Further studies on the biophysical properties on CIC-2 have focused predominantly on Cl⁻ currents, including CIC-2-like inwardly rectifying Cl⁻ currents (3,50-54) and CIC-2 outwardly rectifying Cl⁻ currents (36,37,52,55-59).

CIC-2-like inwardly rectifying Cl⁻ currents have been detected in the human T84 cell line (50), drosophila CIC-2 variants in HEK-293 cells (51) and rat type IV spiral ligament fibrocytes (52). The conductivity sequence of the inwardly rectifying currents is Cl⁻ \geq Br⁻ > I⁻ (3). CIC-2 inwardly rectifying Cl⁻ currents are inhibited by 4,4'-diisothiocyano-2,2'-stilbene-disulfonic acid (DIDS) (3) and Cd²⁺ (50), and regulated by cell

swelling (53), extracellular pH, Cl⁻ and Ca²⁺ (52). However, the results of another study on CIC-2 inwardly rectifying Cl⁻ currents differed, reporting that CIC-2 did not significantly contribute to inward-rectifying anion conductance in the mouse choroid plexus (54).

CIC-2 outwardly rectifying Cl⁻ currents have been found in the T84 human adenocarcinoma cell line (36,37,55), human neurons (56), human parotid acinar cells (57) and rat type IV spiral ligament fibrocytes (52). The outwardly rectifying currents are characterized by a time-dependent decay at depolarizing voltages, and the anion permeability sequence I⁻ > Br⁻ > Cl⁻ > F⁻, and the currents show sensitivity to 1,9-dideoxyforskolin, DIDS (58) and tamoxifen (55). CIC-2 outwardly rectifying Cl⁻ currents are regulated by extracellular pH, Cl⁻ and Ca²⁺ (52). Another study showed that CIC-2 may contribute to cell volume regulation following hyposmotic stress produced by outwardly rectifying Cl⁻ currents, however, cell volume regulation in T84 cells is independent of CIC-2 activity (59).

CIC-2 inwardly/outwardly rectifying Cl⁻ currents are simultaneously found in rat type IV spiral ligament fibrocytes (52), and they are modulated by extracellular pH, Cl⁻ and Ca²⁺. According to previous studies, at least two chloride channels are involved in modulating membrane anion conductance (52). Another study on Cl⁻ currents in rabbit heart cells suggested that rabCIC-2 α /2 β may provide two homologous protein kinase A-activated chloride anion channels, with or without extracellular hypotonicity (60).

4. Functional properties of CIC-2

Previous studies have shown that CIC-2 has several functional properties, including effects on cell volume (2,4,20,35,61), the digestive system (11,16,18,19,62-64), the eye (65-67), respiratory system (11,24,26,68-70), circulatory system (35,71-75) and nervous system (76). In addition, several studies have reported the functions of the NH₂ terminus (77) and carboxy terminus (78) in CIC-2, and the similar functional properties between chloride-selective ion channels, including CIC-2, in protozoa (79-82).

Regulation of cell volume. The activation of CIC-2 in response to cell swelling and low extracellular pH is involved in the dissociation of an NH₂-terminal region of CIC-2 (10). The dephosphorylation of serine/threonine residues in the channel or an associated protein appears to be necessary for current activation following cell swelling in T84 cells (53) and for a CIC-2-like current in ascidian embryo cells during the cell cycle (83). Hypotonic cell swelling activates an outwardly rectifying anionic conductance, with different characteristics from those of CIC-2 previously reported (84). The endogenous currents suggest that protein tyrosine phosphorylation is involved in the signal transduction pathway in certain cell types (85-87), and that epidermal growth factor enhances the hypotonicity-induced anionic efflux (85). However, tyrosine kinase p56^{lck} activates these swelling-sensitive chloride channels without cell swelling, even during cell shrinkage, in lymphocytes (88).

Effect of CIC-2 on the digestive system. Nehrke *et al.* (62) detected the regulatory volume decrease following cell

swelling, which showed that CIC-2 can control cell volume in mouse parotid acinar cells. Other functions of CIC-2 have been reported, including HCl secretion across the parietal cell secretory membrane in the rabbit gastric mucosa (19), mediating the basolateral membrane exit of Cl⁻ in the distal colon of guinea pigs (16), regulating gastric acid secretion (11,18,63), and affecting gastric glands and its cell layers (63). However, one study suggested that CIC-2 may not be a Cl⁻-transporting protein for gastric acid secretion in parietal cells (64).

Effect of CIC-2 on the eye. Previous studies have shown that CIC-2 has a protective effect on trabecular cells under pressure stress (65), can regulate the inward rectification in *Drosophila* retinal photoreceptors (66), and can modulate cellular volume, intracellular Cl⁻ and other cellular functions in trabecular meshwork cells (67).

Effect of CIC-2 on the respiratory, circulatory and nervous systems. CIC-2 is gestationally regulated and is predominantly expressed in the fetal lung (26,68). Cystic fibrosis transmembrane conductance regulator (CFTR)-independent fluid accumulation is induced by keratinocyte growth factor in fetal lung explants (69), and keratinocyte growth factor is necessary for CIC-2-like pH-sensitive Cl⁻ secretion in the fetal airway epithelia (24). It has been shown that CIC-2 affects fetal lung fluid production and lung cyst morphology (70).

It has been reported that a novel Cl⁻ inward rectifier channel is found in the cardiac atrial and ventricular myocytes of several species, including the guinea pig (71-73), mouse (71,73) and rat (72-75). The Cl⁻ inward rectifier channels have properties of activation by hypotonic cell swelling and extracellular acidification, inward rectification, time-dependent slow activation and Cd²⁺-sensitive inhibition (71-75). Experiments have shown that CIC-2 affects the positive chronotropic effect of acute exercise stress (73) and modulates cardiac pacemaker activity (73), but cannot alter intrinsic heart rate (73).

Another study (76) investigating the effect of CIC-2 on inhibitory interneurons showed that membrane voltage-/intracellular chloride-dependent CIC-2 can selectively regulate GABA_A receptor (GABA_A R)-mediated synaptic inputs from basket cells.

5. Mechanisms of CIC-2 regulation by regulators

Cell swelling can increase CIC-2 activity (2,9), and CIC-2 can be activated by hyperpolarization (3,9), extracellular hypotonicity (2) and extracellular acidification (9,10). Previous studies have shown that CIC-2 is also regulated by hormones (89-91), drugs (92-100), proteins (101-107), kinases (108-114), transcription factors (115,116), inhibitors (117-120), scorpion venom (121), α 1-adrenoceptor (122), *Plasmodium berghei* (123), adenosine triphosphate (124,125), ClH₃ (40,126-137), permeant anions (138,139), membrane cholesterol (140) and the tyrosine endocytosis motif (141).

Regulation of CIC-2 by hormones. Thyroid hormones (T3 and T4) can regulate renal function (142,143), Na⁺/K⁺ ATPase (144), Na⁺/H⁺ exchanger (145), and affect kidney growth and development (146). Previous studies have demonstrated that hyperthyroidism and hypothyroidism are associated with




Figure 1. Basic structure of CIC-2 as a two-pore homodimeric channel. CIC-2 is a double-barreled channel with two identical, predominantly independent pores. (A) 18 α -helices are labeled A-R, and the two similar halves within the transmembrane domain (α -helices B-I and J-Q), which are oriented in opposite directions to the membrane, and are shown in green and cyan. The sequence regions, which contribute to the Cl⁻ selectivity filter, are indicated by orange arrows, and the respective conserved sequences are shown; CBS1 is colored red and CBS2 is colored blue. (B) Structure viewed from the extracellular side. The two subunits of the homodimeric protein are shown in red and blue, and bound anions are shown in green. CIC-2, chloride channel 2; CBS, cystathionine- β -synthase.

chloride (147,148), and the reversal of glomerular filtration by T4 is observed in patients with hypothyroidism (149). In addition, a previous study (89) on T4 suggested that CIC-2 is involved in chloride transport regulated by thyroid hormones in rat renal proximal tubules.

Estrogen is associated with a decrease in the urinary excretion of sodium and chloride (150-153). A study by Nascimento *et al* (90) showed that CIC-2 may be involved in estrogen-induced Cl⁻ transport in the rat kidney. Another study (91) showed that CIC-2 is also involved in the rat renal tubule transcellular chloride transport regulated by arginine vasopressin, a neurohypophysial hormone.

Regulation of CIC-2 by drugs. Lubiprostone can induce intestinal fluid secretion (154), treat constipation (155-157) and activate CIC-2 Cl⁻ currents in a concentration-dependent manner (94), and CIC-2 can recover mucosal barrier function in the ischemia-injured intestine (92). Studies have shown that the

activation of CIC-2 by lubiprostone can stimulate the recovery of intestinal barrier function in the ischemia-injured porcine ileum and colon (93), and may have a protective and therapeutic effect on murine models of colitis (99). The prostaglandin E2 receptor 4 [EP (4)] receptor (94-97) can stimulate CIC-2 and CFTR chloride channels, and it has been shown (98) that lubiprostone can activate CFTR by the EP (4) receptor in oocytes. The Chinese medicinal compounds Guanxinkang and diltiazem hydrochloride can decrease the mRNA and protein expression of CIC-2 in rats with myocardial ischemia reperfusion injury (100).

Regulation of CIC-2 by proteins. The functional expression and activation of CIC-2 is reduced by dynein (a protein complex) (101) and p34^{cdc2}/cyclin B (102), however, the interferon- γ glycoprotein can activate CIC-2 in lung epithelial cells through mRNA stabilization, and increase CIC-2 transcripts in Calu-3 cells (107). CIC-2 is regulated by protein phosphatase 1 (102), interactions between the actin cytoskeleton (a filamentous protein structure) and the N-terminus of CIC-2 (104). M phase-specific p34^{cdc2}/cyclin B can phosphorylate the ubiquitination of CIC-2 (103). Heat shock protein 90 can increase CIC-2 current amplitude and the intracellular Cl⁻ concentration, and enhance channel sensitivity to intracellular Cl⁻ (105). CIC-2 is also associated with the transmembrane glycoprotein, GlialCAM, in the brain, and GlialCAM can involve CIC-2 in the homeostasis of myelin, which is defective in leukodystrophy (106).

Regulation of CIC-2 by kinases. CIC-2 membrane abundance is increased by serum and glucocorticoid inducible kinases (SGKs) and decreased by NEDD4-2, an enzyme of the NEDD4 family (108). In rats, protein kinase A can directly phosphorylate CIC-2, whereas protein kinase C and Ca²⁺/calmodulin-dependent protein kinase II cannot (113). PIKfyve is a FYVE finger-containing phosphoinositide kinase (158) and is a potent stimulator of CIC-2-activity (112), which can contribute to the SGK1-dependent regulation of CIC-2 (112).

Janus kinase (JAK) 2 and JAK3 (tyrosine kinase) can down-regulate the activation of CIC-2 and offset Cl⁻ exit (109,111), however, their functions and regulatory mechanism are different. JAK2 is involved in the signaling of leptin (159), growth hormones (160), erythropoietin, thrombopoietin, granulocyte colony-stimulating factor (161) and a variety of cytokines (161,162). JAK2 inhibitors can treat myeloproliferative disorders (163-170), and JAK2 can be activated by hyperosmotic shock (171,172). By contrast, JAK3 can promote proliferation and act against the apoptosis of lymphocytes and tumor cells (173-177). It is also present in acute megakaryoblastic leukemia (178,179). Therefore, cell proliferation and apoptosis is associated with Cl⁻ channel activity (110). In addition, the substitution of lysine by alanine can inactivate JAK3 (180). In addition to JAK2 and JAK3, SPS1-related proline/alanine-rich kinase and oxidative stress-responsive kinase 1 can also downregulate CIC-2 (114).

Regulation of CIC-2 by transcription factors. The Sp1 and Sp3 transcription factors can control the rate of transcription of genetic information from DNA to messenger RNA (181,182). Reducing interactions between Sp1 or Sp3 and the CIC-2

promoter can lead to a postnatal decrease in the expression of CIC-2 in lung epithelia (116). In addition, the glycosylation of SP1 produces the 105-kD isoform of SP1 and is involved in regulating the expression of CIC-2 (115).

Regulation of CIC-2 by inhibitors. Previous studies have shown that CIC-2 is inhibited by methadone (117), gating modifier of anion channels 2 (GATx2) (118), DIDS (119) and 5-nitro-2-(3-phenylpropylamino) benzoic acid (NPPB) (120). However, DASU-02, as an inhibitor of common chloride channels, cannot inhibit CIC-2 (117). The inhibitory effects on CIC-2 by these inhibitors are entirely different. Methadone can inhibit the activities of CIC-2, which shows that CIC-2 may be involved in chloride anion secretion (117). GATx2, as a peptide toxin inhibitor of CIC-2, can inhibit channel activation gating, but not other chloride channels or voltage-gated potassium channels (118). DIDS can significantly reduce the increased mRNA and protein levels of CIC-2 following ischemia-hypoxia damage (119). NPPB, as a CIC inhibitor, can affect the phagocytosis of human trabecular meshwork cells, which shows that CIC-2 may be involved in the regulation of its phagocytic process (120).

Other factors in the functional regulation of CIC-2. According to previous studies, in addition to the above-mentioned regulatory mechanisms, scorpion venom (121), α 1-adrenoceptor (122), *Plasmodium berghei* (123), adenosine triphosphate (124,125), ClH₃ (137), GABA_AR (40,126-128), permeant anions (138,139), membrane cholesterol (140) and β -cyclodextrin sensitive clusters (141) can also regulate or affect CIC-2. A peptide of scorpion venom can induce slower activation kinetics of CIC-2 (121). α 1-adrenoceptor activation can significantly reduce protein levels of CIC-2 in the villus and crypt epithelial cells from the acutely denervated jejunum, but not the innervated jejunum (122). The activation of CIC-2 is involved in the altered permeability caused by *Plasmodium berghei* infection in *Plasmodium berghei*-infected mouse CLCN2 (123). ATP not only decelerates CIC-2 common gating for sufficient electrical stability of neurons (124), it also alters its surface expression (125). Intra-/extra-cellular permeant anions can affect the V_m-dependence of CIC-2 (138). Specially, Cl⁻ as a permeant anion can increase pore occupancy, thus obstructing the closure of the protopore gate of CIC-2 (139). In addition, alterations in the (Cl⁻)_i between 10 and 200 mM can decelerate CIC-2 channel closing at a positive V_m (139). Membrane cholesterol can regulate the activation of CIC-2, and the increased activation of CIC-2 is involved in the relocalization of CIC-2 to detergent-soluble microdomains (140). β -cyclodextrin sensitive clusters with other molecules can maintain CIC-2 activity (141).

Previous studies have reported that ClH₃ encodes the *Caenorhabditis elegans* homologs of CIC-2 (129-131). ClH₃-dependent regulation not only alters the voltage dependence of CIC-2 channels and inhibits hereditary sensory neuropathy (HSN) excitability (137), but may also affect chloride influx (137) in *Caenorhabditis elegans*. However, the chloride efflux pathway of CIC-2 is associated with synaptic inhibition regulated by the GABA_AR (40,126-128). In addition, the HSNs can release acetylcholine, serotonin and multiple neuropeptides (133-136), which excite the VC motor

neurons (132). These functions of HSNs may be associated with *clh-3*-dependent regulation and the voltage dependence of CIC-2 channels.

6. Diseases associated with CIC-2

Previous studies have shown that disruption and abnormality of CIC-2 can cause a number of diseases, including ophthalmological disease (11,183-185), otorhinolaryngological disease (186), disease of the reproductive system (11,187), disease of the respiratory system (188), disease of the digestive system (189-194), disease of the hematological system (195), genetic diseases (23,25,26,42,44,74,76,196-198), diseases of the nervous system (30,40,41,168,199-212) and metabolic diseases (213). The majority of studies have focused on diseases of the nervous system.

Ophthalmological and otorhinolaryngological disease associated with CIC-2. Severe degeneration of the retina occurs in CIC-2-knockout mice, although no other notable eye abnormalities are present (11). Possible reasons for degeneration of the retina caused by CIC-2-knockout include the following (11): i) CIC-2 disruption causes the death of photoreceptor cells; ii) depletion of CIC-2 may impair the transport and alter the ionic environment of photoreceptors. Other studies on ophthalmological diseases associated with CIC-2 include Sjögren's syndrome (183,184,214-218) and age-related cataracts (185).

Sjögren's syndrome is a chronic autoimmune disease, and previous studies have shown that eye diseases caused by Sjögren's syndrome are primarily through the destruction of lacrimal glands (LGs) (214), keratoconjunctivitis sicca (215). In addition, LG pathologic properties in Sjögren's syndrome appear in rabbits induced by autoimmune dacryoadenitis (216-218). Acini and interlobar ducts have the lowest mRNA abundance of CIC2 γ , and the intralobar duct has the highest (183,184), and alterations in CIC2 γ may alter lacrimal secretion, particularly Cl⁻ transport (184). The causes of age-related cataracts include aging, inheritance, local nutritional disorders, immune and metabolic abnormalities, trauma, poisoning and radiation. According to a study by Ouyang (185), the expression level of CIC-2 is associated with the development of age-related cataracts.

Reports on otorhinolaryngological diseases associated with CIC-2 are limited, however, Li *et al* reported on the pathogenesis of nasal polyps. The study (186) showed that CIC-2 was not expressed in normal nasal mucosa, however, CIC-2 proteins were expressed in epithelial cells and sub-epithelial mucous glands in patients affected with nasal polyps. This suggested that CIC-2 is involved in the pathogenesis of nasal polyps.

Diseases of the reproductive system associated with CIC-2. In previous studies, a number of diseases of the reproductive system have been associated with CIC-2, including degeneration of the testes (11) and azoospermia (187,219,220).

It was shown that severe degeneration of the testes appears in CIC-2-knockout mice, however, no other reproductive abnormalities are observed (11). A study by Bösl *et al* suggested that CIC-2 disruption causes the death of germ cells, impaired

transport and alterations to the ionic environment of germ cells, and that germ cells rely on the transepithelial transport mediated by Sertoli cells (11).

Azoospermia is a medical condition in which males do not have a measurable level of sperm in their semen, and is associated with low levels of fertility or infertility. Its pathogenesis involves CFTR disruption in CF, affecting male fertility (219). In addition, the male sterility resulting from reduced fluid volume is associated with disruption of Cl⁻ channels from other CICN genes (220). Another study (187) by Edwards *et al* reported that CICN2nmf240 homozygotes have azoospermic symptoms severe degradation of spermatogenesis, and shortages of spermatocytes, spermatoblasts and sperm.

Diseases of the respiratory system associated with CIC-2. Reports on diseases of the respiratory system associated with CIC-2 are limited. A previous study (188) reported that CIC-2 may be important in the invasion, development and occurrence of lung cancer, and that CIC-2 may be a novel molecular target for clinical therapy in non-small cell lung cancer.

Diseases of the digestive system associated with CIC-2. There have been several reports on diseases of digestive system associated with CIC-2, including constipation (18,26,189-193,221) and repair of impaired intestinal mucosa barrier (194).

CFTR is major chloride channel regulating chloride secretion in the small intestine (221), however, CIC-2 can also regulate chloride secretion (18,26). Hypotonicity can also activate chloride currents in the rat ileum (189). Several studies have reported that CIC-2 is expressed in the intestinal epithelium, in T84 human intestinal cells, rat intestinal tissue (3) and the murine duodenum (190). In addition, previous studies have shown that CIC-2 can regulate chloride secretion in rodent neonatal airways (26), and regulate gastric chloride secretion (18). However, another study (191) described contradictory findings, reporting that CIC-2 was not involved in Cl⁻ secretion, but was involved in Cl⁻ absorption in the distal colon. According to these studies, CIC-2 inhibitors may be used to treat constipation by decreasing NaCl and water absorption in the colon (191).

Irritable bowel syndrome (IBS) is characterized by chronic abdominal pain, discomfort and bloating associated with altered bowel habits, including diarrhea and/or constipation. Current therapy for constipation caused by IBS has side effects, including deterioration of the condition or electrolyte disturbances (192). Previous studies have shown that, in addition to the above-mentioned side effects, lubiprostone can also increase gut motility and frequency of stool passage, relieve abdominal pain and discomfort (192), stimulate chloride secretion and improve bowel function (193).

A previous study (194) by Chen *et al* reported that the activation of CIC-2 can activate tight junction proteins and repair impaired intestinal mucosa barrier. In addition, CIC-2 and tight junction proteins are involved in maintenance of the intestinal mucosal barrier, and acute biliary obstruction-induced destruction of the intestinal mucosa barrier is associated with CIC-2 in enterocytes (194).

Diseases of the hematological system associated with CIC-2. There have been few studies on diseases of the hematological

system associated with CIC-2. A previous study reported the expression of swelling-and/or pH-regulated CIC-2 chloride channels in human leukemia (195). In addition, it was suggested that the molecular identification of chloride channels may provide a novel approach for the treatment of leukemia (195).

Genetic diseases associated with CIC-2. According to previous reports, there have been several studies on the association between CF and CIC-2 (3,11,23,25,26,68,70,196-198,222,223). Several studies have reported that CIC-2 may be an alternative pathway for chloride anion secretion in CF (3,11,23), and that CIC-2 is a potential target for therapy in CF (25,197). CF is a genetic disease, which primarily affects the lungs, in addition to the pancreas, liver, kidneys and intestine (222). CF is caused by mutations in the gene encoding CFTR, the only member of the ABC transporter family known to be a cAMP-activated chloride channel (223). CIC-2 is a candidate alternative chloride channel in respiratory epithelia (196). CIC-2 is also involved in lung morphogenesis (26,68), and can conduct chloride in mature respiratory epithelia (23,25,197). CIC-2 mRNA and protein are expressed in unaffected tissues in CF, which may make up for defects in the expression of CFTR (68).

However, another previous study (198) reported that CIC-2 is unlikely to be a candidate rescue channel in CF, as disruption of CIC-2 and CFTR channel genes did not cause morphological alterations in the intestine, lung or pancreas affected by CF; neither disrupted CIC-2 or CFTR reduced Cl⁻ secretion (198). In addition, two studies (70,196) refer to the importance of detecting modifications of CF by CIC-2, and underlined the importance of examining potential polymorphisms in subjects affected with CF and potential mutations in the coding region of CIC-2.

Diseases of the nervous system associated with CIC-2. There have been more studies on diseases of the nervous system associated with CIC-2, compared with other diseases associated with CIC-2. Studies on diseases of the nervous system associated with CIC-2 have predominantly focused on leukoencephalopathy (199-202,224) and epilepsy (30,40,203-212,225).

Leukoencephalopathy can refer specifically to any of the following diseases: Progressive multifocal leukoencephalopathy, toxic leukoencephalopathy, leukoencephalopathy with vanishing white matter, leukoencephalopathy with neuroaxonal spheroids, reversible posterior leukoencephalopathy syndrome, megalencephalic leukoencephalopathy with subcortical cysts (MLC) and hypertensive leukoencephalopathy. Among these, MLC is a rare type of leukodystrophy, which is characterized by macrocephaly emerging in the first years of life (224).

The disruption of CIC-2 can cause fluid accumulation resulting in myelin vacuolation in mice, similar to that observed in humans affected with MLC from mutations in MLC1 or GlialCAM. GlialCAM is a CIC-2 binding partner and the first auxiliary subunit of CIC-2 (199). According to a study by Jeworutzki *et al* (199), neither the stimulation of GlialCAM on CIC-2 currents, nor mislocalization of this Cl⁻ channel were found to damage glial Cl⁻ transport. Mutated GlialCAM in MLC can target CIC-2 to cell contacts in glia and activate its currents (200). A study by Jeworutzki *et al* (200) showed that GlialCAM can target the common gate deficient CIC-2 mutant, E211V/H816A, to cell contacts without

altering its function. Another study suggested that CIC-2 is not important for MLC1 or GlialCAM localization in the brain (201), but that it is involved in the pathogenesis of MLC (201).

However, a separate study (202) reported different conclusions, as there was no evidence that the CLCN2 gene is associated with MLC. Despite not referring to the association between the CLCN2 gene and MLC, this study demonstrated that mice lacking the CIC-2 protein had white matter abnormalities with vacuole formation in myelin sheaths, similar to the intramyelinic vacuoles in MLC.

Epilepsy comprises a set of neurological diseases characterized by epileptic seizures, and a heterogeneous disorder characterized by recurrent unprovoked seizures, which affect ~1-3% of the population during their lifetimes (225). CIC-2 mRNA and protein are found in neurons and astrocytes (30,40,203). In addition, CIC-2 protein is present at the end feet of astrocytes contacting blood vessels and neurons close to inhibitory synapses (30). Inwardly rectifying hyperpolarization-activated CIC-2-like currents are found in hippocampal pyramidal cells (40,127) and in astrocytes (204-207). In hippocampal pyramidal cells and astrocytes (208), CIC-2 may have different effects. In neurons, CIC-2 can prevent the accumulation of chloride anions above equilibrium due to the activation of CIC-2 by intracellular Cl⁻ (41,127). Under these conditions, GABA_A R activity may become excitatory (208). A previous study (208) reported that loss of function mutations of CIC-2 lead to increased excitability in certain neurons, and that hyperpolarization-activated chloride currents are detected in cortical astrocytes, but absent in tissues from CIC-2-null mice (207). Another study (211) showed that several CIC-2 sequence abnormalities previously found in patients affected with epilepsy are likely to represent innocuous polymorphisms, detected by sequencing of a large collection of human DNA and electrophysiological analysis.

Several other studies have reported that a susceptibility locus for idiopathic generalized epilepsy (IGE) is on chromosome 3q26 (the location of the CLCN2 gene) (209), and three mutations on CIC-2 cosegregated with IGE with autosomal dominant inheritance (210) have been identified.

In addition to the above-mentioned studies on the association between epilepsy and CIC-2, an association between temporal lobe epilepsy (TLE) and CIC-2 has been reported. TLE with spontaneous recurrent attacks, and learning and memory disabilities, is associated with neurodegeneration, abnormal reorganization of the circuitry and loss of functional suppression in hippocampus (212). A study by Ge *et al* reported that CIC-2 contributes towards tonic inhibition, modulated by α 5 subunit-containing GABA_A Rs in the CA1 area (212).

Metabolic diseases associated with CIC-2. Few studies on metabolic diseases associated with CIC-2 have been performed, however, a study on diabetes mellitus was found. Diabetes mellitus is a metabolic disease, which generally causes chronic delayed wound healing. In a study by Pan *et al* (213), a high glucose concentration inhibited keratinocyte migration by downregulating CIC-2, suggesting CIC-2 may be important during delayed wound healing processes. In addition, the study reported that CIC-2 is an important

modulator of cell migration in keratinocytes, although it did not discuss how CIC-2 is involved in keratinocyte migration.

7. Conclusion

With the continuous progress in experimental and clinical studies on the CIC family, it is clear that the activation of CIC-2 occurs via hyperpolarization (3,9), cell swelling (2,9), extracellular hypotonicity (2) and extracellular acidification (9,10), and that the expression of CIC-2 is ubiquitous (3,11) in ureteric bud cells (12), the intestine (13-17), gastric parietal cells (18,19), the liver (20), the lungs (21-25), rat retina (27), parotid acinar cells (28), guinea pig cardiac muscle (29), neuronal cells (30), rat and human airways (17), bovine trabecular meshwork (31), human trabecular meshwork (32,33) and rat trabecular meshwork (34). Although there has been progress in understanding the CLCN2 gene, the molecular structure of the CIC-2 protein, the structure of CIC-2 chloride channels, and the functional properties and mechanisms regulating CIC-2, they remain to be fully elucidated and there have been contradictions in previous studies (226). According to previous studies, it is known that the disruption of CIC-2 can lead to several diseases. Although CIC-2 is associated with the pathogenesis of several diseases, the association between pathogenesis and CIC-2 remains to be fully elucidated.

At present, >6,500 types of genetic disease have been identified, among which ~3,000 are caused by a single gene defect. In this review, the mechanisms underlying the association between the CLCN2 gene and diseases, including azoospermia and IGE, were discussed. In the future, investigations focused on the determination of the CLCN2 gene may identify novel methods to treat and prevent several diseases associated with CIC-2. In addition, as the overexpression and underexpression of CIC-2 can cause diseases, the development of specific CIC-2 activators and inhibitors, and understanding the mechanism of action between the functional properties of CIC-2 and these activators and inhibitors, is required in future investigations to regulate the expression of CIC-2.

As described above, CIC-2 can be regulated by hormones, drugs and scorpion venom. Certain hormones in humans are produced in small quantities, however, they have a substantial effect on health, with underproduction or overproduction leading to a variety of diseases. In addition, scorpion venom can be used to treat cancer and lower blood pressure, and is applied for hemostasis, anticoagulation, as an analgesic and a nerve growth factor. Therefore, future investigations focused on the regulatory mechanisms of hormones, drugs and scorpion venom may assist in developing specific drugs for treating diseases associated with CIC-2.

In conclusion, CIC-2 is important in several diseases and, in order to fully elucidate the structure and function of CIC-2, and the mechanisms regulating CIC-2 associated with disease treatment, examining the associations between CIC-2 and regulators, including hormones, proteins, kinases, transcription factors, scorpion venom, adenosine triphosphate, clh-3, permeant anions, membrane cholesterol, tyrosine endocytosis motif and α 1-adrenoceptor is required to develop novel treatment strategies. Therefore, further investigations are required in the future.

Acknowledgements

The study was supported by the Library of Qiqihar Medical University (grant no. 16TQB04; Qiqihar, China).

References

1. Strange K: Of mice and worms: Novel insights into CIC-2 anion channel physiology. *News Physiol Sci* 17: 11-16, 2002.
2. Gründer S, Thiemann A, Pusch M and Jentsch TJ: Regions involved in the opening of CIC-2 chloride channel by voltage and cell volume. *Nature* 360: 759-762, 1992.
3. Thiemann A, Gründer S, Pusch M and Jentsch TJ: A chloride channel widely expressed in epithelial and non-epithelial cells. *Nature* 356: 57-60, 1992.
4. Furukawa T, Ogura T, Katayama Y and Hiraoka M: Characteristics of rabbit CIC-2 current expressed in *Xenopus* oocytes and its contribution to volume regulation. *Am J Physiol* 274: C500-C512, 1998.
5. Bi MM, Hong S, Zhou HY, Wang HW, Wang LN and Zheng YJ: Chloride channelopathies of CIC-2. *Int J Mol Sci* 15: 218-249, 2013.
6. Middleton RE, Pheasant DJ and Miller C: Homodimeric architecture of a CIC-type chloride ion channel. *Nature* 383: 337-340, 1996.
7. Hsiao SH, Parrish AR, Nahm SS, Abbott LC, McCool BA and Frye GD: Effects of early postnatal ethanol intubation on GABAergic synaptic proteins. *Brain Res Dev Brain Res* 138: 177-185, 2002.
8. Zúñiga L, Niemeyer MI, Varela D, Catalán M, Cid LP and Sepúlveda FV: The voltage-dependent CIC-2 chloride channel has a dual gating mechanism. *J Physiol* 555: 671-682, 2004.
9. Jentsch TJ, Stein V, Weinreich F and Zdebik AA: Molecular structure and physiological function of chloride channels. *Physiol Rev* 82: 503-568, 2002.
10. Jordt SE and Jentsch TJ: Molecular dissection of gating in the CIC-2 chloride channel. *EMBO J* 16: 1582-1592, 1997.
11. Bösl MR, Stein V, Hübner C, Zdebik AA, Jordt SE, Mukhopadhyay AK, Davidoff MS, Holstein AF and Jentsch TJ: Male germ cells and photoreceptors, both depending on close cell-cell interactions, degenerate upon CIC-2 Cl⁻ channel disruption. *EMBO J* 20: 1289-1299, 2001.
12. Huber S, Braun G, Schröppel B and Horster M: Chloride channels CIC-2 and ICln mRNA expression differs in renal epithelial ontogeny. *Kidney Int Suppl* 67: S149-S151, 1998.
13. Gyömörey K, Yeger H, Ackerley C, Garami E and Bear CE: Expression of the chloride channel CIC-2 in the murine small intestine epithelium. *Am J Physiol Cell Physiol* 279: C1787-C1794, 2000.
14. Bali M, Lipecka J, Edelman A and Fritsch J: Regulation of CIC-2 chloride channels in T84 cells by TGF- α . *Am J Physiol Cell Physiol* 280: C1588-C1598, 2001.
15. Mohammad-Panah R, Gyomörey K, Rommens J, Choudhury M, Li C, Wang Y and Bear CE: CIC-2 contributes to native chloride secretion by a human intestinal cell line, Caco-2. *J Biol Chem* 276: 8306-8313, 2001.
16. Catalán M, Cornejo I, Figueroa CD, Niemeyer MI, Sepúlveda FV and Cid LP: CIC-2 in guinea pig colon: mRNA, immunolabeling, and functional evidence for surface epithelium localization. *Am J Physiol Gastrointest Liver Physiol* 283: G1004-G1013, 2002.
17. Lipecka J, Bali M, Thomas A, Fanen P, Edelman A and Fritsch J: Distribution of CIC-2 chloride channel in rat and human epithelial tissues. *Am J Physiol Cell Physiol* 282: C805-C816, 2002.
18. Malinowska DH, Kupert EY, Bahinski A, Sherry AM and Cuppoletti J: Cloning: Functional expression, and characterization of a PKA-activated gastric Cl⁻ channel. *Am J Physiol* 268: C191-C200, 1995.
19. Sherry AM, Malinowska DH, Morris RE, Ciraolo GM and Cuppoletti J: Localization of CIC-2 Cl⁻ channels in rabbit gastric mucosa. *Am J Physiol Cell Physiol* 280: C1599-C1606, 2001.
20. Roman RM, Smith RL, Feranchak AP, Clayton GH, Doctor RB and Fitz JG: CIC-2 chloride channels contribute to HTC cell volume homeostasis. *Am J Physiol Gastrointest Liver Physiol* 280: G344-G353, 2001.
21. Cid LP, Montrose-Rafizadeh C, Smith DI, Guggino WB and Cutting GR: Cloning of a putative human voltage-gated chloride channel (CIC-2) cDNA widely expressed in human tissues. *Hum Mol Genet* 4: 407-413, 1995.

22. Sherry AM, Stroffekova K, Knapp LM, Kupert EY, Cuppoletti J and Malinowska DH: Characterization of the human pH- and PKA-activated CIC-2G(2 alpha) Cl⁻ channel. *Am J Physiol* 273: C384-C393, 1997.
23. Schwiebert EM, Cid-Soto LP, Stafford D, Carter M, Blaisdell CJ, Zeitlin PL, Guggino WB and Cutting GR: Analysis of CIC-2 channels as an alternative pathway for chloride conduction in cystic fibrosis airway cells. *Proc Natl Acad Sci USA* 95: 3879-3884, 1998.
24. Blaisdell CJ, Edmonds RD, Wang XT, Guggino S and Zeitlin PL: pH-regulated chloride secretion in fetal lung epithelia. *Am J Physiol Lung Cell Mol Physiol* 278: L1248-L1255, 2000.
25. Cuppoletti J, Tewari KP, Sherry AM, Kupert EY and Malinowska DH: CIC-2 Cl⁻ channels in human lung epithelia: Activation by arachidonic acid, amidation, and acid-activated omeprazole. *Am J Physiol Cell Physiol* 281: C46-C54, 2001.
26. Murray CB, Morales MM, Flotte TR, McGrath-Morrow SA, Guggino WB and Zeitlin PL: CIC-2: A developmentally dependent chloride channel expressed in the fetal lung and downregulated after birth. *Am J Respir Cell Mol Biol* 12: 597-604, 1995.
27. Enz R, Ross BJ and Cutting GR: Expression of the voltage-gated chloride channel CIC-2 in rod bipolar cells of the rat retina. *J Neurosci* 19: 9841-9847, 1999.
28. Park K, Arreola J, Begenisich T and Melvin JE: Comparison of voltage-activated Cl⁻ channels in rat parotid acinar cells with CIC-2 in a mammalian expression system. *J Membr Biol* 163: 87-95, 1998.
29. Britton FC, Hatton WJ, Rossow CF, Duan D, Hume JR and Horowitz B: Molecular distribution of volume-regulated chloride channels (CIC-2 and CIC-3) in cardiac tissues. *Am J Physiol Heart Circ Physiol* 279: H2225-H2233, 2000.
30. Sik A, Smith RL and Freund TF: Distribution of chloride channel-2-immunoreactive neuronal and astrocytic processes in the hippocampus. *Neuroscience* 101: 51-65, 2000.
31. Srinivas SP, Maertens C, Goon LH, Goon L, Satpathy M, Yue BY, Droogmans G and Nilius B: Cell volume response to hyposmotic shock and elevated cAMP in bovine trabecular meshwork cells. *Exp Eye Res* 78: 15-26, 2004.
32. Comes N, Gasull X, Gual A and Borrás T: Differential expression of the human chloride channel genes in the trabecular meshwork under stress conditions. *Exp Eye Res* 80: 801-813, 2005.
33. Liang W and Zheng YJ: Effect of chloride channel inhibitor in phagocytic process of human trabecular mesh work cells. *Chin J Gerontol* 30: 906-908, 2010.
34. Wang JX, Wang SM and Liu HY: Expression of CIC-2 Chloride channels in rat trabecular meshwork. *Chin J Biologicals* 23: 274-276, 2010.
35. Xiong H, Li C, Garami E, Wang Y, Ramjeesingh M, Galley K and Bear CE: CIC-2 activation modulates regulatory volume decrease. *J Membr Biol* 167: 215-221, 1999.
36. Worrell RT, Butt AG, Cliff WH and Frizzell RA: A volume-sensitive chloride conductance in human colonic cell line T84. *Am J Physiol* 256: C1111-C1119, 1989.
37. Solc CK and Wine JJ: Swelling-induced and depolarization-induced Cl⁻ channels in normal and cystic fibrosis epithelial cells. *Am J Physiol* 261: C658-C674, 1991.
38. Jackson PS and Strange K: Single-channel properties of a volume-sensitive anion conductance. Current activation occurs by abrupt switching of closed channels to an open state. *J Gen Physiol* 105: 643-660, 1995.
39. Strange K, Emma F and Jackson PS: Cellular and molecular physiology of volume-sensitive anion channels. *Am J Physiol* 270: C711-C730, 1996.
40. Smith RL, Clayton GH, Wilcox CL, Escudero KW and Staley KJ: Differential expression of an inwardly rectifying chloride conductance in rat brain neurons: A potential mechanism for cell-specific modulation of postsynaptic inhibition. *J Neurosci* 15: 4057-4067, 1995.
41. Staley K, Smith R, Schaack J, Wilcox C and Jentsch TJ: Alteration of GABAA receptor function following gene transfer of the CLC-2 chloride channel. *Neuron* 17: 543-551, 1996.
42. Chu S and Zeitlin PL: Alternative mRNA splice variants of the rat CIC-2 chloride channel gene are expressed in lung: Genomic sequence and organization of CIC-2. *Nucleic Acids Res* 25: 4153-4159, 1997.
43. Chu S, Murray CB, Liu MM and Zeitlin PL: A short CIC-2 mRNA transcript is produced by exon skipping. *Nucleic Acids Res* 24: 3453-3457, 1996.
44. Chu S, Blaisdell CJ, Liu MZ and Zeitlin PL: Perinatal regulation of the CIC-2 chloride channel in lung is mediated by Sp1 and Sp3. *Am J Physiol* 276: L614-L624, 1999.
45. Dutzler R: The CIC family of chloride channels and transporters. *Curr Opin Struct Biol* 16: 439-446, 2006.
46. Dutzler R: A structural perspective on Cl⁻ channel and transporter function. *FEBS Lett* 581: 2839-2844, 2007.
47. Ramjeesingh M, Li C, Huan LJ, Garami E, Wang Y and Bear CE: Quaternary structure of the chloride channel CIC-2. *Biochemistry* 39: 13838-13847, 2000.
48. Varela D, Niemeyer MI, Cid LP and Sepúlveda FV: Effect of an N-terminus deletion on voltage-dependent gating of the CIC-2 chloride channel. *J Physiol* 544: 363-372, 2002.
49. Stölting G, Fischer M and Fahlke C: CIC-1 and CIC-2 form hetero-dimeric channels with novel protopore functions. *Pflugers Arch* 466: 2191-2204, 2014.
50. Fritsch J and Edelman A: Modulation of the hyperpolarization-activated Cl⁻ current in human intestinal T84 epithelial cells by phosphorylation. *J Physiol* 490: 115-128, 1996.
51. Flores CA, Niemeyer MI, Sepúlveda FV and Cid LP: Two splice variants derived from a *Drosophila melanogaster* candidate CIC gene generate CIC-2-type Cl⁻ channels. *Mol Membr Biol* 23: 149-156, 2006.
52. Qu C, Liang F, Smythe NM and Schulte BA: Identification of CIC-2 and CIC-K2 chloride channels in cultured rat type IV spiral ligament fibrocytes. *J Assoc Res Otolaryngol* 8: 205-219, 2007.
53. Fritsch J and Edelman A: Osmosensitivity of the hyperpolarization-activated chloride current in human intestinal T84 cells. *Am J Physiol* 272: C778-C786, 1997.
54. Speakem T, Kajitam H, Smith CP and Brown PD: Inward-rectifying anion channels are expressed in the epithelial cells of choroid plexus isolated from CIC-2 'knock-out' mice. *J Physiol* 539: 385-390, 2002.
55. Valverde MA, Mintenig GM and Sepúlveda FV: Differential effects of tamoxifen and I⁻ on three distinguishable chloride currents activated in T84 intestinal cells. *Pflugers Arch* 425: 552-554, 1993.
56. Chesnoy-Marchais D: Hyperpolarization-activated chloride channels in Aplysi neurons. In *Chloride Channels and Carriers in Nerve Muscle and Glial Cells* Alvarez-Leefmans, F J Russell J M (eds) New York Plenum Press USA 14. pp367-382, 1990.
57. Arreola J, Park K, Melvin JE and Begenisich T: Three distinct chloride channels control anion movements in rat parotid acinar cells. *J Physiol* 490: 351-362, 1996.
58. Díaz M, Valverde MA, Higgins CF, Rucăreanu C and Sepúlveda FV: Volume-activated chloride channels in HeLa cells are blocked by verapamil and dideoxyforskolin. *Pflugers Arch* 422: 347-353, 1993.
59. Bond TD, Ambikapathy S, Mohammad S and Valverde MA: Osmosensitive Cl⁻ currents and their relevance to regulatory volume decrease in human intestinal T84 cells: Outwardly vs. Inwardly rectifying currents. *J Physiol* 511: 45-54, 1998.
60. Furukawa T, Horikawa S, Terai T, Ogura T, Katayama Y and Hiraoka M: Molecular cloning and characterization of a novel truncated form (CIC-2 beta) of CIC-2 alpha (CIC-2G) in rabbit heart. *FEBS Lett* 375: 56-62, 1995.
61. Chamberlin ME and Strange K: Anisomotic cell volume regulation: A comparative view. *Am J Physiol* 257: C159-C173, 1989.
62. Nehrke K, Arreola J, Nguyen HV, Pilato J, Richardson L, Okunade G, Baggs R, Shull GE and Melvin JE: Loss of hyperpolarization-activated Cl⁻ current in salivary acinar cells from *Clcn2* knockout mice. *J Biol Chem* 277: 23604-23611, 2002.
63. Nighot MP, Nighot PK, Ma TY, Malinowska DH, Shull GE, Cuppoletti J and Blikslager AT: Genetic ablation of the CIC-2 Cl⁻ Channel disrupts mouse gastric parietal cell acid secretion. *PLoS One* 10: e0138174, 2015.
64. Hori K, Takahashi Y, Horikawa N, Furukawa T, Tsukada K, Takeguchi N and Sakai H: Is the CIC-2 chloride channel involved in the Cl⁻ secretory mechanism of gastric parietal cells? *FEBS Lett* 575: 105-108, 2004.
65. Liang W, Zheng WX, Sun LX and Zheng YJ: Effect of chloride channel 2 on trabecular meshwork cells under pressure stress condition. *Chin J Ophthalmol Otorhinolaryngol* 12: 26-29, 2012.
66. Ugarte G, Delgado R, O'Day PM, Farjah F, Cid LP, Vergara C and Bacigalupo J: Putative CIC-2 chloride channel mediates inward rectification in *Drosophila* retinal photoreceptors. *J Membr Biol* 207: 151-160, 2005.

67. Comes N, Abad E, Morales M, Borrás T, Gual A and Gasull X: Identification and functional characterization of CIC-2 chloride channels in trabecular meshwork cells. *Exp Eye Res* 83: 877-889, 2006.
68. Murray CB, Chu S and Zeitlin PL: Gestational and tissue-specific regulation of CIC-2 chloride channel expression. *Am J Physiol* 271: L829-L837, 1996.
69. Zhou L, Graeff RW, McCray PB Jr, Simonet WS and Whitsett JA: Keratinocyte growth factor stimulates CFTR-independent fluid secretion in the fetal lung in vitro. *Am J Physiol* 271: L987-L994, 1996.
70. Blaisdell CJ, Morales MM, Andrade AC, Bamford P, Wasicko M and Welling P: Inhibition of CLC-2 chloride channel expression interrupts expansion of fetal lung cysts. *Am J Physiol Lung Cell Mol Physiol* 286: L420-L426, 2004.
71. Duan D, Ye L, Britton F, Horowitz B and Hume JR: A novel anionic inward rectifier in native cardiac myocytes. *Circ Res* 86: E63-E71, 2000.
72. Britton FC, Wang GL, Huang ZM, Ye L, Horowitz B, Hume JR and Duan D: Functional characterization of novel alternatively spliced CIC-2 chloride channel variants in the heart. *J Biol Chem* 280: 25871-25880, 2005.
73. Huang ZM, Prasad C, Britton FC, Ye LL, Hatton WJ and Duan D: Functional role of CLC-2 chloride inward rectifier channels in cardiac sinoatrial nodal pacemaker cells. *Mol Cell Cardiol* 47: 121-132, 2009.
74. Komukai K, Brette F and Orchard CH: Electrophysiological response of rat atrial myocytes to acidosis. *Am J Physiol Heart Circ Physiol* 283: H715-H724, 2002.
75. Komukai K, Brette F, Pascarel C and Orchard CH: Electrophysiological response of rat ventricular myocytes to acidosis. *Am J Physiol Heart Circ Physiol* 283: H412-H422, 2002.
76. Földy C, Lee SH, Morgan RJ and Soltesz I: Regulation of fast-spiking basket cell synapses by the chloride channel CIC-2. *Nat Neurosci* 13: 1047-1049, 2010.
77. Cid LP, Niemeyer MI, Ramírez A and Sepúlveda FV: Splice variants of a CIC-2 chloride channel with differing functional characteristics. *Am J Physiol Cell Physiol* 279: C1198-C1210, 2000.
78. Garcia-Olivares J, Alekov A, Boroumand MR, Begemann B, Hidalgo P and Fahlke C: Gating of human CIC-2 chloride channels and regulation by carboxy-terminal domains. *J Physiol* 586: 5325-5336, 2008.
79. Eckmann L and Gillin FD: Microbes and microbial toxins: Paradigms for microbial-mucosal interactions I. Pathophysiological aspects of enteric infections with the lumen dwelling protozoan pathogen *Giardia lamblia*. *Am J Physiol Gastrointest Liver Physiol* 280: G1-G6, 2001.
80. Upcroft P and Upcroft JA: Drug targets and mechanisms of resistance in the anaerobic protozoa. *Clin Microbiol Rev* 14: 150-164, 2001.
81. Hawrelak J: Giardiasis: Pathophysiology and management. *Altern Med Rev* 8: 129-142, 2003.
82. Moreno-Galindo EG, Rodríguez-Eliás JC, Ramírez-Herrera MA, Sánchez-Chapula JA and Navarro-Polanco RA: The principal conductance in *Giardia lamblia* trophozoites possesses functional properties similar to the mammalian CIC-2 current. *Pflugers Arch* 466: 915-924, 2014.
83. Villaz M, Cinniger JC and Moody WJ: A voltage-gated chloride channel in ascidian embryos modulated by both the cell cycle clock and cell volume. *J Physiol* 488: 689-699, 1995.
84. Okada Y: Volume expansion-sensing outward-rectifier Cl⁻ channel: Fresh start to the molecular identity and volume sensor. *Am J Physiol* 273: C755-C789, 1997.
85. Tilly BC, van den Berghe N, Tertoolen LG, Edixhoven MJ and de Jonge HR: Protein tyrosine phosphorylation is involved in osmoregulation of ionic conductances. *J Biol Chem* 268: 19919-19922, 1993.
86. Sorota S: Tyrosine protein kinase inhibitors prevent activation of cardiac swelling-induced chloride current. *Pflugers Arch* 431: 178-185, 1995.
87. Voets T, Manolopoulos V, Eggermont J, Ellory C, Droogmans G and Nilius B: Regulation of a swelling-activated chloride current in bovine endothelium by protein tyrosine phosphorylation and G proteins. *J Physiol* 506: 341-352, 1998.
88. Lepple-Wienhues A, Szabó I, Laun T, Kaba NK, Gulbins E and Lang F: The tyrosine kinase p56lck mediates activation of swelling-induced chloride channels in lymphocytes. *J Cell Biol* 141: 281-286, 1998.
89. Santos Ornellas D, Grozovsky R, Goldenberg RC, Carvalho DP, Fong P, Guggino WB and Morales M: Thyroid hormone modulates CIC-2 chloride channel gene expression in rat renal proximal tubules. *J Endocrinol* 178: 503-511, 2003.
90. Nascimento DS, Reis CU, Goldenberg RC, Ortega-Carvalho TM, Pazos-Moura CC, Guggino SE, Guggino WB and Morales MM: Estrogen modulates CIC-2 chloride channel gene expression in rat kidney. *Pflugers Arch* 446: 593-599, 2003.
91. Morales MM, Nascimento DS, Capella MA, Lopes AG and Guggino WB: Arginine vasopressin regulates CFTR and CIC-2 mRNA expression in rat kidney cortex and medulla. *Pflugers Arch* 443: 202-211, 2001.
92. Moeser AJ, Haskell MM, Shifflett DE, Little D, Schultz BD and Blikslager AT: CIC-2 chloride secretion mediates prostaglandin-induced recovery of barrier function in ischemia-injured porcine ileum. *Gastroenterology* 127: 802-815, 2004.
93. Moeser AJ, Nighot PK, Engelke KJ, Ueno R and Blikslager AT: Recovery of mucosal barrier function in ischemic porcine ileum and colon is stimulated by a novel agonist of the CIC-2 chloride channel, lubiprostone. *Am J Physiol Gastrointest Liver Physiol* 292: G647-G656, 2007.
94. Cuppoletti J, Malinowska DH, Tewari KP, Li QJ, Sherry AM, Patchen ML and Ueno R: SPI-0211 activates T84 cell chloride transport and recombinant human CIC-2 chloride currents. *Am J Physiol Cell Physiol* 287: C1173-C1183, 2004.
95. Bao HF, Liu L, Self J, Duke BJ, Ueno R and Eaton DC: A synthetic prostone activates apical chloride channels in A6 epithelial cells. *Am J Physiol Gastrointest Liver Physiol* 295: G234-G251, 2008.
96. Bijvelds MJ, Bot AG, Escher JC and De Jonge HR: Activation of intestinal Cl⁻ secretion by lubiprostone requires the cystic fibrosis transmembrane conductance regulator. *Gastroenterology* 137: 976-985, 2009.
97. Ao M, Venkatasubramanian J, Boonkaewwan C, Ganesan N, Syed A, Benya RV and Rao MC: Lubiprostone activates Cl⁻ secretion via cAMP signaling and increases membrane CFTR in the human colon carcinoma cell line, T84. *Dig Dis Sci* 56: 339-351, 2011.
98. Norimatsu Y, Moran AR and MacDonald KD: Lubiprostone activates CFTR, but not CIC-2, via the prostaglandin receptor (EP4). *Biochem Biophys Res Commun* 426: 374-379, 2012.
99. Jin Y, Pridgen TA and Blikslager AT: Pharmaceutical activation or genetic absence of CIC-2 alters tight junctions during experimental colitis. *Inflamm Bowel Dis* 21: 2747-2757, 2015.
100. Qiu SB, Liang Y and Liu P: Effect of CIC-2/CIC-3 CFTR expression in rats affected with the myocardial ischemia reperfusion injury by Chinese native medicine compound Guangxinkang. *Chin J Integrative Med Cardio-/Cerebrovascular Dis* 11: 1482-1485, 2013.
101. Dhani SU, Mohammad-Panah R, Ahmed N, Ackerley C, Ramjeesingh M and Bear CE: Evidence for a functional interaction between the CIC-2 chloride channel and the retrograde motor dynein complex. *J Biol Chem* 278: 16262-16270, 2003.
102. Furukawa T, Ogura T, Zheng YJ, Tsuchiya H, Nakaya H, Katayama Y and Inagaki N: Phosphorylation and functional regulation of CIC-2 chloride channels expressed in *Xenopus* oocytes by M cyclin-dependent protein kinase. *J Physiol* 540: 883-893, 2002.
103. Zheng YJ, Furukawa T, Ogura T, Tajimi K and Inagaki NM: M phase-specific expression and phosphorylation-dependent ubiquitination of the CIC-2 channel. *J Biol Chem* 277: 32268-32273, 2002.
104. Ahmed N, Ramjeesingh M, Wong S, Varga A, Garami E and Bear CE: Chloride channel activity of CIC-2 is modified by the actin cytoskeleton. *Biochem J* 352: 789-794, 2000.
105. Hinzpeter A, Lipecka J, Brouillard J, Baudoin-Legros M, Dadlez M, Edelman A and Fritsch J: Association between Hsp90 and the CIC-2 chloride channel upregulates channel function. *Am J Physiol Cell Physiol* 290: C45-C56, 2006.
106. Pérez-Rius C, Gaitán-Peñas H, Estévez R and Barrallo-Gimeno A: Identification and characterization of the zebrafish CIC-2 chloride channel orthologs. *Pflugers Arch* 467: 1769-1781, 2015.
107. Chu S, Blaisdell CJ, Bamford P and Ferro TJ: Interferon-gamma regulates CIC-2 chloride channel in lung epithelial cells. *Biochem Biophys Res Commun* 324: 31-39, 2004.
108. Palmada M, Dieter M, Boehmer C, Waldegger S and Lang F: Serum and glucocorticoid inducible kinases functionally regulate CIC-2 channels. *Biochem Biophys Res Commun* 321: 1001-1006, 2004.
109. Hosseinzadeh Z, Bhavsar SK and Lang F: Downregulation of CIC-2 by JAK2. *Cell Physiol Biochem* 29: 737-742, 2012.

110. Lang F, Föllner M, Lang K, Lang P, Ritter M, Vereninov A, Szabo I, Huber SM and Gulbins E: Cell volume regulatory ion channels in cell proliferation and cell death. *Methods Enzymol* 428: 209-225, 2007.
111. Warsi J, Elvira B, Hosseinzadeh Z, Shumilina E and Lang F: Downregulation of chloride channel CIC-2 by Janus kinase 3. *J Membr Biol* 247: 387-393, 2014.
112. Klaus F, Laufer J, Czarkowski K, Strutz-Seebohm N, Seebohm G and Lang F: PIKfyve-dependent regulation of the Cl⁻ channel CIC-2. *Biochem Biophys Res Commun* 381: 407-411, 2009.
113. Park K, Begenisich T and Melvin JE: Protein kinase A activation phosphorylates the rat CIC-2 Cl⁻ channel but does not change activity. *J Membr Biol* 182: 31-37, 2001.
114. Warsi J, Hosseinzadeh Z, Elvira B, Bissinger R, Shumilina E and Lang F: Regulation of CIC-2 activity by SPAK and OSR1. *Kidney Blood Press Res* 39: 378-387, 2014.
115. Vij N and Zeitlin PL: Regulation of the CIC-2 lung epithelial chloride channel by glycosylation of Sp1. *Am J Respir Cell Mol Biol* 34: 754-759, 2006.
116. Holmes KW, Hales R, Chu S, Maxwell MJ, Mogayzel PJ Jr and Zeitlin PL: Modulation of Sp1 and Sp3 in lung epithelial cells regulates CIC-2 chloride channel expression. *Am J Respir Cell Mol Biol* 29: 499-505, 2003.
117. Cuppoletti J, Chakrabarti J, Tewari KP and Malinowska DH: Differentiation between human CIC-2 and CFTR Cl⁻ channels with pharmacological agents. *Am J Physiol Cell Physiol* 307: C479-C492, 2014.
118. Thompson CH, Olivetti PR, Fuller MD, Freeman CS, McMaster D, French RJ, Pohl J, Kubanek J and McCarty NA: Isolation and characterization of a high affinity peptide inhibitor of CIC-2 chloride channels. *J Biol Chem* 284: 26051-26062, 2009.
119. Zhao B, Quan H, Ma T, Tian Y, Cai Q and Li H: 4,4'-Diisothiocyanostilbene-2,2'-disulfonic Acid (DIDS) ameliorates ischemia-hypoxia-induced white matter damage in neonatal rats through inhibition of the voltage-gated chloride channel CIC-2. *Int J Mol Sci* 16: 10457-10469, 2015.
120. Liang W and Zheng YJ: Effect of interfered CIC-2 gene expression on cell cycle of human trabecular mesh work cells. *Chin J Gerontol* 30: 1070-1072, 2010.
121. Thompson CH, Fields DM, Olivetti PR, Fuller MD, Zhang ZR, Kubanek J and McCarty NA: Inhibition of CIC-2 chloride channels by a peptide component or components of scorpion venom. *J Membr Biol* 208: 65-76, 2005.
122. Baglole CJ, Sigalet DL and Meddings JB: Alpha1-adrenoceptors down-regulate CIC-2 chloride channels in epithelial cells from the acutely denervated jejunum. *Eur J Pharmacol* 565: 202-206, 2007.
123. Huber SM, Duranton C, Henke G, Van De Sand C, Heussler V, Shumilina E, Sandu CD, Tanneur V, Brand V, Kasinathan RS, *et al.*: Plasmodium induces swelling-activated CIC-2 anion channels in the host erythrocyte. *J Biol Chem* 279: 41444-41452, 2004.
124. Stölting G, Teodorescu G, Begemann B, Schubert J, Nabbout R, Toliat MR, Sander T, Nürnberg P, Lerche H and Fahlke C: Regulation of CIC-2 gating by intracellular ATP. *Pflugers Arch* 465: 1423-1437, 2013.
125. Dhani SU, Kim Chiaw P, Huan LJ and Bear CE: ATP depletion inhibits the endocytosis of CIC-2. *J Cell Physiol* 214: 273-280, 2008.
126. Madison DV, Malenka RC and Nicoll RA: Phorbol esters block a voltage-sensitive chloride current in hippocampal pyramidal cells. *Nature* 321: 695-697, 1986.
127. Staley K: The role of an inwardly rectifying chloride conductance in postsynaptic inhibition. *J Neurophysiol* 72: 273-284, 1994.
128. Rinke I, Artmann J and Stein V: CIC-2 voltage-gated channels constitute part of the background conductance and assist chloride extrusion. *J Neurosci* 30: 4776-4786, 2010.
129. Schriever AM, Friedrich T, Pusch M and Jentsch TJ: CLC chloride channels in *Caenorhabditis elegans*. *J Biol Chem* 274: 34238-34244, 1999.
130. Nehrke K, Begenisich T, Pilato J and Melvin JE: Into ion channel and transporter function. *Caenorhabditis elegans* CIC-type chloride channels: Novel variants and functional expression. *Am J Physiol Cell Physiol* 279: C2052-C2066, 2000.
131. Denton J, Nehrke K, Rutledge E, Morrison R and Strange K: Alternative splicing of N- and C-termini of a *C. Elegans* CIC channel alters gating and sensitivity to external Cl⁻ and H⁺. *J Physiol* 555: 97-114, 2004.
132. Zhang M, Chung SH, Fang-Yen C, Craig C, Kerr RA, Suzuki H, Samuel AD, Mazur E and Schafer WR: A self-regulating feed-forward circuit controlling *C. Elegans* egg-laying behavior. *Curr Biol* 18: 1445-1455, 2008.
133. Desai C and Horvitz HR: *Caenorhabditis elegans* mutants defective in the functioning of the motor neurons responsible for egg laying. *Genetics* 121: 703-721, 1989.
134. Lickteig KM, Duerr JS, Frisby DL, Hall DH, Rand JB and Miller DM III: Regulation of neurotransmitter vesicles by the homeodomain protein UNC-4 and its transcriptional corepressor UNC-37/groucho in *Caenorhabditis elegans* cholinergic motor neurons. *J Neurosci* 21: 2001-2014, 2001.
135. Nathoo AN, Moeller RA, Westlund BA and Hart AC: Identification of neuropeptide-like protein gene families in *Caenorhabditis elegans* and other species. *Proc Natl Acad Sci USA* 98: 14000-14005, 2001.
136. Kim K and Li C: Expression and regulation of an FMRamide-related neuropeptide gene family in *Caenorhabditis elegans*. *J Comp Neuro* 475: 540-550, 2004.
137. Branicky R, Miyazaki H, Strange K and Schafer WR: The voltage-gated anion channels encoded by *clh-3* regulate egg laying in *C. Elegans* by modulating motor neuron excitability. *J Neurosci* 34: 764-775, 2014.
138. Niemeyer MI, Cid LP, Yusef YR, Briones R and Sepúlveda FV: Voltage-dependent and -independent titration of specific residues accounts for complex gating of a CIC chloride by extracellular protons. *J Physiol* 587: 1387-1400, 2009.
139. Sánchez-Rodríguez JE, De Santiago-Castillo JA and Arreola J: Permeant anions contribute to voltage dependence of CIC-2 chloride channel by interacting with the protopore gate. *J Physiol* 588: 2545-2556, 2010.
140. Hinzpeter A, Fritsch J, Borot F, Trudel S, Vieu DL, Brouillard F, Baudouin-Legros M, Clain J, Edelman A and Ollero M: Membrane cholesterol content modulates CIC-2 gating and sensitivity to oxidative stress. *J Biol Chem* 282: 2423-2432, 2007.
141. Cornejo I, Niemeyer MI, Zúñiga L, Yusef YR, Sepúlveda FV and Cid LP: Rapid recycling of CIC-2 chloride channels between plasma membrane and endosomes: Role of a tyrosine endocytosis motif in surface retrieval. *J Cell Physiol* 221: 650-657, 2009.
142. Light DB, Schwiebert EM, Karlson KH and Stanton BA: Atrial natriuretic peptide inhibits a cation channel in renal inner medullary collecting duct cells. *Science* 243: 393-395, 1999.
143. Masilamani S, Kim GH, Mitchell C, Wade JB and Knepper MA: Aldosterone-mediated regulation of ENaC alpha, beta, and gamma subunit proteins in rat kidney. *J Clin Invest* 104: R19-R23, 1999.
144. Ewart HS and Klip A: Hormonal regulation of the Na(+)-K(+)-ATPase: Mechanisms underlying rapid and sustained changes in pump activity. *Am J Physiol* 269: C295-C311, 1995.
145. Morales MM, Brucoli HCP, Malnic G and Lopes AG: Role of thyroid hormones in renal tubule acidification. *Mol Cell Biochem* 154: 17-21, 1996.
146. Katz AI, Emmanouel DS and Lindheimer MD: Thyroid hormone and the kidney. *Nephron* 15: 223-249, 1975.
147. Shirota T, Shinoda T, Yamada T and Aizawa T: Alteration of renal function in hyperthyroidism: Increased tubular secretion of creatinine and decreased distal tubule delivery of chloride. *Metabolism* 41: 402-405, 1992.
148. Liu XM, Bai Y and Guo ZS: Study on urinary function and metabolism of water and electrolytes in primary hypothyroidism. *Zhonghua Nei Ke Za Zhi* 29: 299-302, 1990 (In Chinese).
149. Capasso G, De Tommaso G, Pica A, Anastasio P, Capasso J, Kinne R and De Santo NG: Effects of thyroid hormones on heart and kidney functions. *Miner Electrolyte Metab* 25: 57-74, 1999.
150. Weir RJ, Briggs E, Mack A, Naismith L, Taylor L and Wilson E: Blood pressure in women taking oral contraceptives. *Br Med J* 1: 533-535, 1974.
151. Meade TW, Haines AP, North WR, Chakrabarti R, Howarth DJ and Stirling Y: Haemostatic, lipid, and blood-pressure profiles of women on oral contraceptives containing 50 microgram or 30 microgram oestrogen. *Lancet* 2: 948-951, 1977.
152. Seeger H, Armbruster FP, Mueck AO and Lippert TH: The effect of estradiol on urodilatin production in postmenopausal women. *Arch Gynecol Obstet* 262: 65-68, 1998.
153. Brunette MG and Leclerc M: Effect of estrogen on calcium and sodium transport by the nephron luminal membranes. *J Endocrinol* 170: 441-450, 2001.

154. Ueno R, Osama H, Habe T, Engelke K and Patchen M: Oral SPI-0211 increases intestinal fluid secretion and chloride concentration without altering serum electrolyte levels (Abstract). *Gastroenterology* 126: A-298, 2004.
155. Johanson JF, Gargano M, Hollan PC, Patchen ML and Ueno R: Phase III efficacy and safety of RU-0211, a novel chloride channel activator, for the treatment of constipation. *Gastroenterology* 124: A48, 2003.
156. Johanson JF, Gargano MA, Holland PC, Patchen ML and Ueno R: Phase III randomized withdrawal study of RU-0211 a novel chloride channel activator for the treatment of constipation (Abstract). *Gastroenterology* 126: A-100, 2004.
157. Lacy BE and Levy LC: Lubiprostone: A chloride channel activator. *J Clin Gastroenterol* 41: 345-351, 2007.
158. Shisheva A, Sbrissa D and Lkonomov O: Cloning, characterization, and expression of a novel Zn²⁺-binding FYVE finger-containing phosphoinositide kinase in insulin-sensitive cells. *Mol Cell Biol* 19: 623-634, 1999.
159. Morris DL and Rui L: Recent advances in understanding leptin signaling and leptin resistance. *Am J Physiol Endocrinol Metab* 297: E1247-E1259, 2009.
160. Brooks AJ and Waters MJ: The growth hormone receptor: Mechanism of activation and clinical implications. *Nat Rev Endocrinol* 6: 515-525, 2010.
161. Spivak JL: Narrative review: Thrombocytosis, polycythemia vera, and JAK2 mutations: The phenotypic mimicry of chronic myeloproliferation. *Ann Intern Med* 152: 300-306, 2010.
162. Lopez AF, Hercus TR, Ekert P, Littler DR, Guthridge M, Thomas D, Ramshaw HS, Stomski F, Perugini M, D'Andrea R, *et al*: Molecular basis of cytokine receptor activation. *IUBMB Life* 62: 509-518, 2010.
163. Tefferi A, Skoda R and Vardiman JW: Myeloproliferative neoplasms: Contemporary diagnosis using histology and genetics. *Nat Rev Clin Oncol* 6: 627-637, 2009.
164. Baskin R, Majumder A and Sayeski PP: The recent medicinal chemistry development of Jak2 tyrosine kinase small molecule inhibitors. *Curr Med Chem* 17: 4551-4558, 2010.
165. Ho K, Valdez F, Garcia R and Tirado CA: JAK2 Translocations in hematological malignancies: Review of the literature. *J Assoc Genet Technol* 36: 107-109, 2010.
166. Oh ST and Gotlib J: JAK2 V617F and beyond: Role of genetics and aberrant signaling in the pathogenesis of myeloproliferative neoplasms. *Expert Rev Hematol* 3: 323-337, 2010.
167. Tefferi A: Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. *Leukemia* 24: 1128-1138, 2010.
168. Pardanan A, Vannucchi AM, Passamonti F, Cervantes F, Barbui T and Tefferi A: JAK inhibitor therapy for myelofibrosis: Critical assessment of value and limitations. *Leukemia* 25: 218-225, 2011.
169. Santos FP and Verstovsek S: JAK2 inhibitors: What's the true therapeutic potential? *Blood Rev* 25: 53-63, 2011.
170. Mahfouz RA, Hoteit R, Salem Z, Bazarbachi A, Mugharbel A, Farhat F, Ziyadeh A, Ibrahim A and Taher A: JAK2 V617F gene mutation in the laboratory work-up of myeloproliferative disorders: Experience of a major referral center in Lebanon. *Genet Test Mol Biomarkers* 15: 263-265, 2011.
171. Gatsios P, Terstegen L, Schliess F, Häussinger D, Kerr IM, Heinrich PC and Graeve L: Activation of the Janus kinase/signal transducer and activator of transcription pathway by osmotic shock. *J Biol Chem* 273: 22962-22968, 1998.
172. Garnovskaya MN, Mukhin YV, Vlasova TM and Raymond JR: Hypertonicity activates Na⁺/H⁺ exchange through Janus kinase 2 and calmodulin. *J Biol Chem* 278: 16908-16915, 2003.
173. Uckun FM, Vassilev A, Dibirdik I and Tibbles H: Targeting JAK3 tyrosine kinase-linked signal transduction pathways with rationally-designed inhibitors. *Anticancer Agents Med Chem* 7: 612-623, 2007.
174. de Toter D, Meazza R, Capaia M, Fabbi M, Azzarone B, Balleri E, Gobbi M, Cutrona G, Ferrarini M and Ferrini S: The opposite effects of IL-15 and IL-21 on CLL B cells correlate with differential activation of the JAK/STAT and ERK1/2 pathways. *Blood* 111: 517-524, 2008.
175. Fainstein N, Vaknin I, Einstein O, Zisman P, Ben Sasson SZ, Baniyash M and Ben-Hur T: Neural precursor cells inhibit multiple inflammatory signals. *Mol Cell Neurosci* 39: 335-341, 2008.
176. Nakayama J, Yamamoto M, Hayashi K, Satoh H, Bundo K, Kubo M, Goitsuka R, Farrar MA and Kitamura D: BLNK suppresses pre-B-cell leukemogenesis through inhibition of JAK3. *Blood* 113: 1483-1492, 2009.
177. Kim BH, Oh SR, Yin CH, Lee S, Kim EA, Kim MS, Sandoval C, Jayabose S, Bach EA, Lee HK and Baeg GH: MS-1020 is a novel small molecule that selectively inhibits JAK3 activity. *Br J Haematol* 148: 132-143, 2010.
178. Walters DK, Mercher T, Gu TL, O'Hare T, Tyner JW, Loriaux M, Goss VL, Lee KA, Eide CA, Wong MJ, *et al*: Activating alleles of JAK3 in acute megakaryoblastic leukemia. *Cancer Cell* 10: 65-75, 2006.
179. Malinge S, Ragu C, Della-Valle V, Pisani D, Constantinescu SN, Perez C, Villeval JL, Reinhardt D, Landman-Parker J, Michaux L, *et al*: Activating mutations in human acute megakaryoblastic leukemia. *Blood* 112: 4220-4226, 2008.
180. Haan C, Rolvinger C, Raulf F, Kapp M, Drückes P, Thoma G, Behrmann I and Zerwes HG: Jak1 has a dominant role over Jak3 in signal transduction through γ c-containing cytokine receptors. *Chem Biol* 18: 314-323, 2011.
181. Karin M: Too many transcription factors: Positive and negative interactions. *New Biol* 2: 126-131, 1990.
182. Latchman DS: Transcription factors: An overview. *Int J Biochem Cell Biol* 29: 1305-1312, 1997.
183. Nandoskar P, Wang Y, Wei R, Liu Y, Zhao P, Lu M, Huang J, Thomas P, Trousdale MD and Ding C: Changes of chloride channels in the lacrimal glands of a rabbit model of Sjögren syndrome. *Cornea* 31: 273-279, 2012.
184. Ding C, Parsa L, Nandoskar P, Zhao P, Wu K and Wang Y: Duct system of the rabbit lacrimal gland: Structural characteristics and role in lacrimal secretion. *Invest Ophthalmol Vis Sci* 51: 2960-2967, 2010.
185. Ouyang WB: Correlation between CIC-2 chloride channel and age related cataract Master's thesis. Dalian Med Univ Dalian, 2013.
186. Li HB, Han DM, Zhong B, Fan EZ and Liu ZY: Expressions of chloride channel CIC-2 and CIC-3 in human nasal polyps. *J Clin Otorhinolaryngol* 17: 266-277, 2003.
187. Edwards MM, Marin de Evsikova C, Collin GB, Gifford E, Wu J, Hicks WL, Whiting C, Varvel NH, Maphis N, Lamb BT, *et al*: Photoreceptor degeneration, azoospermia, leukoencephalopathy, and abnormal RPE cellfunction in mice expressing an early stop mutation in CLCN2. *Invest Ophthalmol Vis Sci* 51: 3264-3272, 2010.
188. Xu ZN, Zheng XY, Zhao W, Xin H and Han ZG: Expression and significance of chloride channel CIC-2 in nonsmall-cell lung cancer. *Chin J Lab Diagn* 16: 60-62, 2012.
189. Diener M, Bertog M, Fromm M and Scharrer E: Segmental heterogeneity of swelling-induced Cl⁻ transport in rat small intestine. *Pflugers Arch* 432: 293-300, 1996.
190. Joo NS, Clarke LL, Han BH, Forte LR and Kim HD: Cloning of CIC-2 chloride channel from murine duodenum and its presence in CFTR knockout mice. *Biochim Biophys Acta* 1446: 431-437, 1999.
191. Catalán MA, Flores CA, González-Begne M, Zhang Y, Sepúlveda FV and Melvin JE: Severe defects in absorptive ion transport in distal colons of mice that lack CIC-2 channels. *Gastroenterology* 142: 346-354, 2012.
192. Lacy BE and Chey WD: Lubiprostone: Chronic constipation and irritable bowel syndrome with constipation. *Expert Opin Pharmacother* 10: 143-152, 2009.
193. Crowell MD, Harris LA, DiBaise JK and Olden KW: Activation of type-2 chloride channels: A novel therapeutic target for the treatment of chronic constipation. *Curr Opin Invest Drugs* 8: 66-70, 2007.
194. Chen ZY, Wang YG, Yang P, Huang WG, Zhou YS and Feng XS: Relationship between CIC-2 and intestinal mucosal barrier in rats with obstructive jaundice. *World Chin J Digestology* 19: 2829-2834, 2011.
195. Jiang B, Hattori N, Liu B, Kitagawa K and Inagaki C: Expression of swelling- and/or pH-regulated chloride channels (CIC-2,3,4 and 5) in human leukemic and normal immune cells. *Life Sci* 70: 1383-1394, 2002.
196. Blaisdell CJ, Howard TD, Bamford P, Bleecker ER and Stine OC: CLC-2 single nucleotide polymorphisms (SNPs) as potential modifiers of cystic fibrosis disease severity. *BMC Med Genet* 5: 26, 2004.
197. Cuppoletti J, Tewari KP, Sherry AM, Kupert EY and Malinowska DH: Human CIC-2- chloride channels can be activated Potential for therapy in cystic fibrosis. *Faseb J* 15: A847, 2001.
198. Zdebek AA, Cuffe JE, Bertog M, Korbmacher C and Jentsch TJ: Additional disruption of the CIC-2 Cl(-) channel does not exacerbate the cystic fibrosis phenotype of cystic fibrosis transmembrane conductance regulator mouse models. *J Biol Chem* 279: 22276-22283, 2004.

199. Jeworutzki E, López-Hernández T, Capdevila-Nortes X, Sirisi S, Bengtsson L, Montolio M, Zifarelli G, Arnedo T, Müller CS, Schulte U, *et al*: GlialCAM, a protein defective in a leukodystrophy, serves as a CIC-2 Cl(-) channel auxiliary subunit. *Neuron* 73: 951-961, 2012.
200. Jeworutzki E, Lagostena L, Elorza-Vidal X, López-Hernández T, Estévez R and Pusch M: GlialCAM a CLC-2 Cl(-) channel subunit activates the slow gate of CLC chloride channels. *Biophys J* 107: 1105-1116, 2014.
201. Hoegg-Beiler MB, Sirisi S, Orozco IJ, Ferrer I, Hohensee S, Auberson M, Gödde K, Vilches C, de Heredia ML, Nunes V, *et al*: Disrupting MLC1 and GlialCAM and CIC-2 interactions in leukodystrophy entails glial chloride channel dysfunction. *Nat Commun* 5: 3475, 2014.
202. Scheper GC, van Berkel CG, Leisle L, de Groot KE, Errami A, Jentsch TJ and Van der Knaap MS: Analysis of CLCN2 as candidate gene for megalencephalic leukoencephalopathy with subcortical cysts. *Genet Test Mol Biomarkers* 14: 255-257, 2010.
203. Gulácsi A, Lee CR, Sik A, Viitanen T, Kaila K, Tepper JM and Freund TF: Cell type-specific differences in chloride-regulatory mechanisms and GABA(A) receptor-mediated inhibition in rat *substantia nigra*. *J Neurosci* 23: 8237-8246, 2003.
204. Ferroni S, Marchini C, Nobile M and Rapisarda C: Characterization of an inwardly rectifying chloride conductance expressed by cultured rat cortical astrocytes. *Glia* 21: 217-227, 1997.
205. Nobile M, Pusch M, Rapisarda C and Ferroni S: Single-channel analysis of a CIC-2-like chloride conductance in cultured rat cortical astrocytes. *FEBS Lett* 479: 10-14, 2000.
206. Makara JK, Pethö GL, Tóth A and Spät A: pH-sensitive inwardly rectifying chloride current in cultured rat cortical astrocytes. *Glia* 34: 52-58, 2001.
207. Makara JK, Rappert A, Matthias K, Steinhäuser C, Spät A and Kettenmann H: Astrocytes from mouse brain slices express CIC-2-mediated Cl- currents regulated during development and after injury. *Mol Cell Neurosci* 23: 521-530, 2003.
208. Niemeyer MI, Yusef YR, Cornejo I, Flores CA, Sepúlveda FV and Cid LP: Functional evaluation of human CIC-2 chloride channel mutations associated with idiopathic generalized epilepsies. *Physiol Genomics* 19: 74-83, 2004.
209. Sander T, Schulz H, Saar K, Gennaro E, Riggio MC, Bianchi A, Zara F, Luna D, Bulteau C, Kaminska A, *et al*: Genome search for susceptibility loci of common idiopathic generalised epilepsies. *Hum Mol Genet* 9: 1465-1472, 2000.
210. Haug K, Warnstedt M, Alekov AK, Sander T, Ramirez A, Poser B, Maljevic S, Hebeisen S, Kubisch C, Rebstock J, *et al*: Mutations in CLCN2 encoding a voltage-gated chloride channel are associated with idiopathic generalized epilepsies. *Nat Genet* 33: 527-532, 2003.
211. Blanz J, Schweizer M, Auberson M, Maier H, Muenscher A, Hübner CA and Jentsch TJ: Leukoencephalopathy upon disruption of the chloride channel CIC-2. *J Neurosci* 27: 6581-6589, 2007.
212. Ge YX, Liu Y, Tang HY, Liu XG and Wang X: CIC-2 contributes to tonic inhibition mediated by $\alpha 5$ subunit-containing GABA(A) receptor in experimental temporal lobe epilepsy. *Neuroscience* 186: 120-127, 2011.
213. Pan F, Guo R, Cheng W, Chai L, Wang W, Cao C and Li S: High glucose inhibits CIC-2 chloride channels and attenuates cell migration of rat keratinocytes. *Drug Des Devel Ther* 9: 4779-4791, 2015.
214. Borchers AT, Naguwa SM, Keen CL and Gershwin ME: Immunopathogenesis of Sjögren's syndrome. *Clin Rev Allergy Immunol* 25: 89-104, 2003.
215. Nocturne G and Mariette X: Advances in understanding the pathogenesis of primary Sjogren's syndrome. *Nat Rev Rheumatol* 9: 544-556, 2013.
216. Guo Z, Song D, Azzarolo AM, Schechter JE, Warren DW, Wood RL, Mircheff AK and Kaslow HR: Autologous lacrimal lymphoid mixed-cell reactions induce dacryoadenitis in rabbits. *Exp Eye Res* 71: 23-31, 2000.
217. Zhu Z, Stevenson D, Schechter JE, Mircheff AK, Atkinson R and Trousdale MD: Lacrimal histopathology and ocular surface disease in a rabbit model of autoimmune dacryoadenitis. *Cornea* 22: 25-32, 2003.
218. Thomas PB, Zhu Z, Selvam S, Samant DM, Stevenson D, Mircheff AK, Schechter JE, Song SW and Trousdale MD: Autoimmune dacryoadenitis and keratoconjunctivitis induced in rabbits by subcutaneous injection of autologous lymphocytes activated *ex vivo* against lacrimal antigens. *J Autoimmun* 31: 116-122, 2008.
219. Chan HC, Ruan YC, He Q, Chen MH, Chen H, Xu WM, Chen WY, Xie C, Zhang XH and Zhou Z: The cystic fibrosis transmembrane conductance regulator in reproductive health and disease. *J Physiol* 587: 2187-2195, 2009.
220. Yeung CH, Barfield JP and Cooper TG: Chloride channels in physiological volume regulation of human spermatozoa. *Biol Reprod* 73: 1057-1063, 2005.
221. Anderson MP, Sheppard DN, Berger HA and Welsh M: Chloride channels in the apical membrane of normal and cystic fibrosis airway and intestinal epithelia. *Am J Physiol* 263: L1-L14, 1992.
222. O'Sullivan BP and Freedman SD: Cystic fibrosis. *Lancet* 373: 1891-1904, 2009.
223. Riordan JR, Rommens JM, Kerem B, Alon N, Rozmahel R, Grzelczak Z, Zielenski J, Lok S, Plavsic N, Chou JL, *et al*: Identification of the cystic fibrosis gene: Cloning and characterization of complementary. *Science* 245: 1066-1073, 1989.
224. Van der Knaap MS, Barth PG, Stroink H, van Nieuwenhuizen O, Arts WF, Hoogenraa F and Valk J: Leukoencephalopathy with swelling and a discrepantly mild clinical course in eight children. *Ann Neurol* 37: 324-334, 1995.
225. Hauser WA, Annegers JF and Rocca WA: Descriptive epidemiology of epilepsy: Contributions of population-based studies from Rochester, Minnesota. *Mayo Clin Proc* 71: 576-586, 1996.
226. Ji ZY: Research progress of chloride channel CIC- 2. *J Kunm Med Univ* 30: 68-72, 2009.